Fulgent Q1 2026 Revenue Falls, Losses Widen Amid Diagnostics Headwinds

What happened

Fulgent Genetics reported Q1 2026 revenue of $71.1M, a decline from $84.1M in Q3 2025, and a GAAP loss of $0.80 per share, missing expectations. Non-GAAP loss was $0.36 per share, and adjusted EBITDA loss was $15.2M, signaling continued operational strain. The diagnostics business, which relies on a single customer for 23% of revenue, faces pressure from potential reimbursement cuts and volume variability. Meanwhile, therapeutic R&D spending is ramping, with management targeting $35-50M in 2026, increasing cash burn. Despite a cash cushion of ~$788M, the revenue trajectory and persistent losses challenge the investment thesis of near-term operating leverage.

Implication

Longer-term, the large cash balance ($788M) provides a floor, but the thesis now requires a clear reversal in diagnostics growth and cost containment. If the next quarter does not show improvement, the bear case (down to $18) becomes more probable. The 23% customer concentration and therapeutic cash burn remain key risks.

Thesis delta

The Q1 2026 results significantly weaken the base case assumption of mid-teens revenue growth and near-breakeven operations. The revenue decline and persistent operating losses push the expected path to profitability further out, increasing the probability of the bear scenario. Investors should demand visible improvement in diagnostics revenue and margin stability before re-rating the stock.